Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6941196 | 0.89 | P2RX7 (0.49) | P2RX7GHSRMTNR1AMTNR1BFAAH | |
| SCHEMBL366547 | 0.83 | P2RX7 (0.55) | P2RX7GHSRMTNR1AMTNR1BFAAH | |
| SCHEMBL6584070 | 0.81 | P2RX7 (0.53) | P2RX7GHSRMTNR1AMTNR1BFAAH | |
| SCHEMBL8569917 | 0.81 | GHSR (0.57) | P2RX7GHSRMTNR1AMTNR1BFAAH | |
| SCHEMBL6584064 | 0.81 | P2RX7 (0.53) | P2RX7GHSRMTNR1AMTNR1BFAAH | |
| SCHEMBL7072071 | 0.79 | P2RX7 (0.46) | P2RX7GHSRMTNR1AMTNR1BFAAH | |
| SCHEMBL6642213 | 0.79 | GHSR (0.69) | P2RX7GHSR | |
| SCHEMBL25518906 | 0.78 | GHSR (0.53) | P2RX7GHSRMTNR1AMTNR1BFAAH | |
| SCHEMBL6534185 | 0.77 | FAAH (0.53) | P2RX7GHSRMTNR1AMTNR1BFAAH | |
| SCHEMBL6427539 | 0.77 | FAAH (0.53) | P2RX7GHSRMTNR1AMTNR1BFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | HOECHST AKTIENGESELLSCHAFT | 2004-03-04 | — | — | US | disclosed |
| US-6632840-B1 | Inhibiting the Na+/H+ exchanger, treating at least one of arrhythmias and shock | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | disclosed |
| US-6436999-B1 | REACTING GUANIDINE AND CARBOCYCLIC ACIDS, TO FORM COMPOUNDS LIKE BIS(3-METHYLSULFONYL-4-I-PROPYLBENZOYL)GUANIDINE, USED FOR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS AND AS PRODRUGS FOR SODIUM CHANNEL MODULATORS TO CONTROL BLOOD PRESSURE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | ADRA1B, ADRA1A, HYOU1 | P2RX7 1876/4885GHSR 1452/4885MTNR1A 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.